Overview of Purilin

What is Purilin? Defining its Identity and Purpose

Property	Description
Active Ingredient	Levosalbutamol (Levalbuterol)
Pharmacological Class	Selective beta2-Adrenergic Receptor Agonist (Bronchodilator)
Common Use	Relief of constricted air passages (bronchospasm)
Origin	Synthetic (Single-isomer formulation)
Forms	Solution for nebulization, Inhalation Aerosol, Syrup, Tablet

What Type of Medicine is Purilin (Levosalbutamol)?

Purilin is a prescription-only medication primarily used in respiratory care, containing the active component Levosalbutamol, recognized internationally as Levalbuterol. It belongs to the Short-acting Selective beta2-Adrenergic Receptor Agonist class, a pharmacological identity commonly grouped with Bronchodilators.

A key feature differentiating Levosalbutamol is that it is a single-isomer formulation. This means the drug is chemically purified to contain only the therapeutically active R-isomer, maximizing the intended action. This specific chemical structure is clinically recognized for its focused action on the airways, supporting its role in addressing the narrowing of air passages.

Forms and Basic Composition of the Preparation

Levosalbutamol is typically administered via inhalation for direct delivery to the lungs, making its primary preparations an Inhalation Aerosol (Metered-Dose Inhaler or MDI) and a Solution for Nebulization. Alternative oral formulations, including Syrup and Tablets, are also available, often tailored for patient groups such as children. The active ingredient, present as Levosalbutamol Sulphate, is a single-active ingredient product. This substance is combined with standard pharmaceutical bases appropriate for the chosen delivery system.

What is the Primary Action and General Purpose?

The primary physiological action of Purilin is the relaxation of bronchial smooth muscle, a mechanism that directly leads to the widening of the air passages known as bronchodilation. The general purpose of this medication is therefore to provide prompt, symptomatic relief when the patient experiences acute, temporary tightening and constriction of the airways. By counteracting this muscle tension, Purilin helps to improve airflow and rapidly address the difficulties associated with acute bronchospasm and other symptoms of reversible obstructive airway disease.

Regulatory References

MedlinePlus Levalbuterol Drug Information

What side effects are possible with Purilin?

Possible side effects and safety information

The official safety profile for Purilin (Levosalbutamol) reflects the potential for adverse effects typical of its pharmacological class, as categorized by frequency and the body system affected in regulatory documents.

Frequency-Classified Adverse Reactions

Adverse reactions are classified according to incidence, ranging from Very Common (ge 1/10) to Very Rare (<1/10,000) based on official labeling

Frequency Category	Representative Examples by System Organ Class (SOC)
Very Common	Tremor (Nervous System)
Common	Headache, Tachycardia (Increased Heart Rate), Palpitations, Muscle cramps
Rare/Very Rare	Cardiac arrhythmias, Hypokalemia (Low Potassium), Hypersensitivity Reactions

Serious Adverse Reactions and Safety Constraints

Regulatory documents highlight several serious adverse reactions. These include Paradoxical Bronchospasm—an immediate, life-threatening worsening of breathing that may occur, particularly upon first use of an inhaled form. Other serious events noted are severe Hypersensitivity Reactions (e.g., Anaphylaxis) and clinically significant Cardiovascular Effects.

Safety notes specify the potential for Hypokalemia and beta-agonist-associated Electrocardiogram (ECG) changes.

Condition-Related Safety Considerations

Caution is advised for patients with pre-existing conditions such as certain cardiovascular disorders (e.g., hypertension, coronary insufficiency), diabetes mellitus, hyperthyroidism, or convulsive disorders. The drug's safety profile also includes notes on exposure; for example, reactions like tremor and nervousness may be more pronounced at the start of therapy but may diminish with continued, regular use.

Overdose and Emergency Response

Purilin Overdose and When to Seek Help

This information reflects the documented official profile for Purilin overdosage as established by government regulatory authorities.

Documented Overdose Manifestations

Overdose presentations typically involve an exaggeration of the drug's known effects on the central nervous and cardiovascular systems. Manifestations may include profound drowsiness, dizziness, and loss of coordination (ataxia). Severe outcomes officially listed include significant respiratory depression, potentially leading to respiratory arrest, and cardiovascular instability, such as severe hypotension and cardiac arrhythmias.

Emergency Action Requirements

Urgent medical attention is required immediately upon suspicion of Purilin overdose or the appearance of any signs of severe toxicity (e.g., difficulty breathing, collapse, or unresponsiveness). Regulatory documents mandate that patients be transported to a medical facility for immediate and specialized supportive care. Contacting local Emergency Services or a certified Poison Control Center is the required first step.

Management and Monitoring

Management in a clinical setting is defined as supportive and symptomatic. Healthcare professionals will focus on maintaining vital functions, including airway patency and circulatory stability. Continuous cardiac monitoring (e.g., ECG) and observation of respiratory function are officially required procedures. Specific measures, such as the use of activated charcoal for gastrointestinal decontamination, may be considered by physicians under defined circumstances (e.g., within one hour of ingestion).

There may be special considerations documented for specific populations, such as pediatric patients or those with existing kidney impairment, due to potentially altered sensitivity or elimination rates.

Therapeutic Uses of Purilin

Therapeutic Applications

Purilin is a pharmacological agent primarily indicated for the treatment of certain hematological and autoimmune conditions. Its mechanism of action focuses on modulating the immune system and influencing the production and function of specific blood cells.

Primary Indications

Chronic Lymphocytic Leukemia (CLL): Purilin is utilized in the management of this type of cancer which affects the blood and bone marrow. It works by interfering with the growth and spread of malignant lymphocytes.
Non-Hodgkin Lymphoma (NHL): The medication is used to treat various forms of lymphoma, helping to reduce tumor size and manage the progression of the disease.
Autoimmune Disorders: In certain cases where the immune system attacks the body's own tissues, Purilin may be prescribed to suppress this overactive immune response.

Anticipated Benefits

The primary goal of treatment with Purilin is to achieve clinical stabilization or remission of the underlying condition. Key benefits observed during therapy include:

Reduction in Lymphadenopathy: A decrease in the size of enlarged lymph nodes, which is a common manifestation of lymphoproliferative disorders.
Hematological Improvement: Stabilization of blood cell counts, including red blood cells and platelets, which may be compromised by the primary disease.
Splenomegaly Management: Reduction in the size of an enlarged spleen, potentially alleviating associated abdominal discomfort.
Symptom Control: Improvement in systemic symptoms such as fatigue, night sweats, and unexplained weight loss associated with chronic hematological conditions.

Eligibility and Restrictions for Use

Purilin (levosalbutamol) is indicated for use in adults, adolescents, and children 6 years of age to treat or prevent bronchospasm associated with reversible obstructive airway disease.

Who Cannot Use Purilin (Contraindications)

Purilin is contraindicated and must not be used by patients with a known history of hypersensitivity or allergic reaction to levosalbutamol or any of its components.

Populations Requiring Caution or Restriction

Use of Purilin is not recommended or requires special consideration in several patient groups, as noted in regulatory documents:

Pediatric Patients: Safety and efficacy have not been established for use in children under 6 years of age.
Pregnancy and Lactation: The drug should only be used during pregnancy if the potential benefit justifies the potential risk to the fetus. Caution should be exercised when administered to a nursing woman as it is unknown if the drug passes into human milk.
Coexisting Conditions: Particular caution and close medical monitoring are advised for patients with certain medical problems, including acute severe asthma, cardiovascular disorders (such as coronary insufficiency, hypertension, or cardiac arrhythmias), hyperthyroidism, diabetes mellitus, or convulsive disorders. Caution is also necessary for patients with impaired renal function.

What should I know about interactions with other medicines?

Purilin (prulifloxacin), as a member of the fluoroquinolone antibiotic class, is associated with specific drug interactions that may necessitate avoidance or close clinical monitoring.

Medications to Use with Caution or Avoid

The most clinically significant interaction is with corticosteroids (such as hydrocortisone or prednisolone). Concomitant use of Purilin and a corticosteroid is advised to be avoided as it significantly increases the risk of serious musculoskeletal side effects, including tendinitis and tendon rupture. This elevated risk is particularly noted in older patients, those with renal impairment, and individuals who have undergone solid organ transplantation.

Purilin can also inhibit the liver enzyme CYP1A2, which can increase the blood levels of medicines metabolized by this enzyme, such as theophylline and certain antipsychotics or antidepressants. This interaction may lead to an increased risk of side effects from those co-administered drugs. Additionally, co-administration with non-steroidal anti-inflammatory drugs (NSAIDs), like fenbufen, may potentially increase the risk of central nervous system effects, such as convulsions.

Absorption-Affecting Agents

The absorption of Purilin from the gut may be significantly reduced by products containing aluminum, magnesium (e.g., antacids), iron, calcium, or zinc. To minimize this effect, Purilin must be administered either two hours before or at least four hours after the ingestion of these types of products. Dairy products and calcium-fortified beverages can also reduce absorption, and their simultaneous use should be avoided.

Note: Patients with a history of serious adverse reactions associated with any quinolone or fluoroquinolone medicine should generally not use Purilin.

Mechanism of Action

Selective Activation of the beta2-Adrenergic Receptor System

The primary function of Purilin involves the high-affinity binding of its R-enantiomer to the beta2-adrenergic receptors found on airway smooth muscle. This specific molecular interaction initiates the G s protein/Adenylyl Cyclase cascade, resulting in a rapid surge of intracellular cAMP and subsequent inhibition of muscle contraction. The mechanism establishes the drug's short-acting duration, as it directly produces relaxation of the bronchial smooth muscle (bronchodilation), a process that reverses the physiological state of airway smooth muscle contraction.

Isomer Specificity and Regulation of Cellular Dynamics

The drug's mechanism is defined by its single-isomer purity, which results in a formulation defined by the R-enantiomer's high affinity and specificity. The absence of the S-enantiomer removes the potential for its divergent effects on receptor kinetics and cellular Ca^2+ mobilization. Beyond muscle relaxation, the sustained cAMP signaling generated by the active isomer modulates cellular dynamics by modulating mast cell function, resulting in a reduction of constrictive mediator release, and by enhancing mucociliary clearance. This pathway adjustment contributes to the functional changes observed within the respiratory system.

Dosage and Administration Information

How to use Purilin (Proleukin/Aldesleukin): Official Administration Guidelines

Purilin (aldesleukin, marketed as Proleukin) is administered under strict medical supervision using a specific procedural protocol. This section outlines the official administration instructions without discussing therapeutic indications or safety information.

Administration Scope

Feature	Official Requirement
Route of Administration	Intravenous (IV) infusion only
Dosing Schedule	600,000 International Units (IU) per kilogram of body weight
Timing in Relation to Meals	Not specified in administration procedures
Age-Group Rules	Indicated for use in adults

Procedural and Preparation Requirements

Purilin is supplied as a lyophilized (freeze-dried) cake in a single-use vial. Prior to administration, the contents of the vial must be reconstituted with 1.2 mL of Sterile Water for Injection, USP.

Administration Method: The prepared solution is administered as a 15-minute intravenous infusion. Treatment is typically given every 8 hours for up to 5 consecutive days (a total of up to 14 doses in this initial period).

Missed-Dose and Withholding Rules: Doses are frequently withheld based on the patient's clinical status, particularly upon the development of moderate to severe lethargy or somnolence. The continuation of therapy is contingent upon the reversal of these clinical manifestations. Following the initial 5-day cycle, a mandatory 9-day no-treatment rest period must be observed before the subsequent treatment cycle may begin.

Connection to the Overall Use Protocol The administration of this medication involves a precise, cyclical regimen of short intravenous infusions that is highly contingent on the patient's immediate response to the previous dose. This protocol includes weight-based dosing and mandated rest periods, ensuring the entire procedure follows the established clinical framework for drug delivery.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Purilin (Levosalbutamol)

Evidence for Use in Acute and Chronic Asthma

The research on Purilin primarily was studied for conditions characterized by fluctuating or episodic manifestations, such as asthma, and research examined symptoms related to acute airway narrowing. Studies have included Randomized Controlled Trials (RCTs) and multi-center research, which are widely recognized study designs in medical research. These trials was evaluated in settings exploring short-term symptom changes in adults and children with asthma. Researchers examined functional outcomes related to systemic or functional imbalance, such as changes in the Forced Expiratory Volume in 1 second ( FEV1). Research describes patterns observed related to changes in lung function over the short term. Some trials reported how symptoms evolved in the observed populations and described patterns in systemic effects when compared to the racemic form of Salbutamol.

Evidence for Use in Exercise-Induced Bronchospasm (EIB)

Studies explored the use of Purilin in conditions involving periods of heightened symptoms brought on by exercise, known as Exercise-Induced Bronchospasm. These involved specific types of studies, often Randomized, Double-Blind, Placebo-Controlled, Cross-Over Studies. The primary outcomes describing episodic or acute changes that research examined focused on outcomes related to functional measures, monitoring the maximum change in FEV1 after a standardized exercise challenge. Follow-up durations were limited in this area, centering on acute administration.

What is Still Uncertain About Purilin (Evidence Gaps)

Long-term effects are not fully established with the same level of detailed evidence as short-term effects. Currently, there is limited information for long-term outcomes from large-scale studies extending beyond a few months. Comparative evidence is lacking in large-scale studies directly comparing the long-term functional impact against other bronchodilator compounds. Sample sizes were modest in some specific subgroup analyses, meaning that the subgroup findings are uncertain.

Key Studies & References Levalbuterol prevents exercise-induced bronchospasm in adolescents and adults with asthma

Frequently Asked Questions (FAQ)

Common questions about Purilin (FAQ)

Q: Does Purilin cause unusual dreams or sleep disturbances?

Regulatory documents indicate that Insomnia, or difficulty sleeping, is an adverse reaction that has been reported, based on postmarketing experience. Concerns about sleep disturbances should be discussed with a healthcare provider.

Q: Can Purilin be taken with common over-the-counter pain relievers?

Official information warns of potential interactions with certain Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), such as Fenbufen. Since many common over-the-counter pain relievers belong to this class, questions regarding the use of specific OTC products should be directed to a healthcare provider.

Q: Is it normal to feel a little dizzy when first starting Purilin?

Yes, regulatory documents list dizziness as a common adverse reaction observed in clinical trials with Purilin. Like other common side effects, this effect may be more noticeable when first starting the medication.

Q: What happens if I miss a dose of Purilin?

If a dose is missed, the recommended approach is generally to take the next dose at its regularly scheduled time. It is important to remember that extra doses should not be taken to try and make up for a missed one.

Q: Does taking Purilin long-term reduce its effectiveness?

The drug label contains a warning that a need for more doses of Purilin than usual is a marker of asthma deterioration. This suggests a reduction in the drug's expected effectiveness, and this situation warrants a consultation with a healthcare provider for a medical review.

Q: Is it okay to drive while taking Purilin?

Common side effects of Purilin include dizziness and tremor. Official guidance advises caution about performing hazardous tasks, such as driving or operating heavy machinery, until an individual knows how the medication affects them. Guidance on performing such activities should be discussed with a healthcare provider.

Q: Is Purilin known to cause stomach upset or nausea?

Yes, according to the official product information, nausea and vomiting are listed as adverse reactions. These effects have been observed in clinical trials or reported through postmarketing data.

Q: What are the signs of a rare but serious side effect from Purilin?

Signs of serious reactions include an immediate worsening of breathing (Paradoxical Bronchospasm) or signs of a severe allergic reaction, such as hives or swelling of the face. Signs of low potassium (hypokalemia), like muscle weakness or an irregular heartbeat, may also be relevant and require immediate attention.

Q: Does Purilin interact with alcohol, and how severe is the risk?

The official product information does not list a direct drug-to-alcohol interaction with Purilin. However, for some individuals, alcohol consumption can potentially worsen symptoms of asthma or other obstructive airway diseases. Concerns about alcohol and Purilin use should be reviewed with a healthcare provider.

Q: Does Purilin come in different strengths, and why?

Yes, Purilin is available in different strengths, depending on the chosen formulation. These different strengths are necessary to accommodate various methods of delivery, such as a solution for nebulization versus a metered-dose inhalation aerosol (MDI).

Q: Is it possible to develop a tolerance to Purilin over time?

The drug label warns that a need to use the medication more frequently than prescribed may signal a deterioration of the underlying condition. This situation can be associated with a reduced response to the drug and warrants a medical review with a healthcare provider.

Q: What should I do if the expected effect of Purilin doesn't seem to be happening?

Official warnings state that if the usual response is not achieved, or if breathing problems worsen, it may signal an instability in the condition. This situation warrants a medical review with a healthcare provider for a reevaluation of the patient and the treatment regimen.

Q: Can Purilin cause changes in appetite?

While not a common side effect, official documents note that loss of appetite has been associated with certain severe adverse reactions, such as an overdose or dangerously low potassium levels (hypokalemia).

Q: How does the action of Purilin compare to other drugs in the same class?

The mechanism is distinguished by Purilin's single-isomer purity. The drug contains only the R-enantiomer, which is intended to provide a more focused action on the beta2 receptors compared to the prototype drug in the same class, which is a racemic mixture.

Q: Does Purilin interact with cold and flu medicines?

Official labeling contains a warning about potential interactions with other sympathomimetic drugs. Since many cold and flu medicines contain these active ingredients, combining them with Purilin could enhance effects such as an increased heart rate or elevated blood pressure.

Q: Can Purilin affect the results of lab tests?

Yes, Purilin can potentially cause a temporary drop in potassium levels in the blood (Hypokalemia) and may also be associated with changes seen on an electrocardiogram (ECG changes). These are both results often seen in laboratory or diagnostic tests.

Q: Why is Purilin only available by prescription?

The product is classified as a Prescription Drug (Rx-only) due to its potent pharmacological action, the potential for serious adverse effects, and the need for proper diagnosis and continuous medical monitoring to ensure its safe and effective use.

Q: Does Purilin cause dry mouth or blurred vision?

Official adverse event reports, including postmarketing data, list both dry mouth and blurred vision as possible side effects. The exact incidence, or how often they occur, is not precisely known.

Q: Are there any long-term effects of Purilin that are still being studied?

Clinical studies have primarily focused on the drug's immediate, short-term functional outcomes. Official documents state that the long-term effects of this product are not fully established with the same level of detailed evidence as the short-term effects.

Q: Why do some people feel worse before they feel better on Purilin?

A serious, but rare, risk listed in the warnings is Paradoxical Bronchospasm. This is an immediate, life-threatening worsening of breathing that can occur, especially when the inhaled form is used for the first time. If this serious adverse reaction occurs, prompt medical attention is required.

Q: What's the difference between Purilin and [Similar Drug Name]?

Purilin is the single-isomer formulation of the prototype drug, containing only the therapeutically active R-enantiomer. The specific chemical purity is designed for a more focused action on the beta2 receptors, in contrast to the prototype, which is a racemic mixture containing both R- and S-enantiomers.

Q: How long does Purilin typically stay in your system after stopping it?

According to official pharmacokinetics data, the mean elimination half-life of Levosalbutamol is typically between 3.3 to 4 hours. This time frame indicates how quickly the drug is cleared from the body.

Q: Can people with kidney problems safely take Purilin?

Yes, but official warnings state that caution is necessary for patients with impaired renal function. Close medical monitoring by a healthcare provider is advised when the drug is used in this patient population.

Q: Is it safe to take Purilin if I have a history of heart problems?

Purilin can cause changes to the cardiovascular system, such as increases in heart rate and blood pressure. Therefore, it should be used with caution in patients with underlying cardiovascular disorders, including hypertension, coronary insufficiency, or cardiac arrhythmias.

Q: How should Purilin be stored—does it need to be refrigerated?

Official storage instructions state that Purilin should be kept at room temperature (20^circ to 25 C or 68^circ to 77 F). The medication, especially the inhalation solution or aerosol forms, should not be frozen.

Q: Are there different forms of Purilin (e.g., tablet, capsule, liquid)?

Yes, Purilin is available in multiple forms to suit different needs, including a Solution for Nebulization, an Inhalation Aerosol (MDI), and oral formulations such as Tablets and Syrup. Official documents do not list a capsule form.

How should Purilin be stored and disposed of?

How to Store and Dispose of Purilin (Levosalbutamol)

The official storage conditions for Purilin (Levosalbutamol) are defined by the medication's form, and strict adherence is required to maintain product stability.

Storage Parameter	Inhalation Solution	Inhalation Aerosol
Required Temperature	20^circ to 25 C (68^circ to 77 F)	20^circ to 25 C (68^circ to 77 F)
Prohibited Conditions	Do not freeze; Protect from light.	Do not freeze; Do not expose above 49 C (120 F)

All forms must be stored out of the sight and reach of children. For the Inhalation Solution, vials must be kept in the foil pouch and used within two weeks of opening the pouch. The Inhalation Aerosol must be discarded when the dose counter reads zero. The pressurized canister must not be punctured, incinerated, or thrown into a fire.

Purilin